Natera, Inc. filed a pre‑market approval (PMA) application with the U.S. Food and Drug Administration on February 2, 2026 for its Signatera™ CDx companion diagnostic, a tumor‑informed circulating tumor DNA assay that detects molecular residual disease in patients with muscle‑invasive bladder cancer (MIBC). The filing follows the landmark IMvigor011 phase‑3 trial, which demonstrated that Signatera‑positive patients treated with atezolizumab achieved significant improvements in disease‑free survival and overall survival compared with placebo, while Signatera‑negative patients had a low risk of recurrence without adjuvant therapy. The trial results were presented at the European Society for Medical Oncology Congress in October 2025 and published in the New England Journal of Medicine, providing robust clinical evidence to support the regulatory submission.
Natera’s PMA filing is a strategic milestone that could position Signatera as the first companion diagnostic MRD test to guide adjuvant therapy in bladder cancer. If approved, the test would expand coverage beyond its current indications for non‑small cell lung cancer and colorectal cancer, potentially unlocking a new revenue stream in a market where MIBC accounts for 20‑25% of newly diagnosed cases and bladder cancer ranks as the sixth most common cancer in the United States. The company’s preliminary Q4 2025 results—revenue of approximately $660 million, a 39% year‑over‑year increase—highlight a strong growth trajectory that management attributes to record gains in women’s health, organ health, and oncology segments. The Signatera portfolio alone saw a 52% year‑over‑year increase in clinical testing volumes in Q1 2025, underscoring the product’s commercial momentum.
Management emphasized the significance of the PMA submission, with Alexey Aleshin, general manager of oncology and corporate chief medical officer, describing it as “an important step toward making MRD‑guided treatment a reality for patients with muscle‑invasive bladder cancer.” CEO Steve Chapman noted that the company’s “record gains and confidence in continued growth through 2026” are driven by strong demand across core segments and a growing pipeline of companion diagnostics.
Analysts and investors have reacted positively to the regulatory filing, citing Natera’s robust financial performance and the potential for expanded reimbursement. TD Cowen raised its price target for the company from $240 to $280 in early January 2026, citing strong Q4 2025 earnings and a promising outlook for the diagnostics industry. The market reaction is largely driven by the company’s ability to consistently deliver strong results, maintain high margins, and expand its product portfolio in high‑growth areas.
The PMA submission also signals Natera’s continued focus on strategic investments in high‑return verticals. The company has been working to expand reimbursement for its tests, with CMS coverage for surveillance in non‑small cell lung cancer achieved in February 2025 and pan‑cancer coverage policies announced in March 2023. The Signatera test is also being integrated into other clinical trials, such as the NRG Oncology ARCHER trial, to evaluate its utility in monitoring treatment response and disease recurrence. These efforts reinforce Natera’s competitive moat in the cfDNA diagnostics space and position the company to capture a larger share of the growing companion diagnostic market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.